AMLSG 21-13 (#539)
Laufzeit: 01.01.2016 - 31.12.2040
Kurzfassung
Randomized phase III study of intensive chemotherapy with or without Dasatinib (Sprycel) in adult patients with newly diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Laufzeit: 01.01.2016 - 31.12.2040
Randomized phase III study of intensive chemotherapy with or without Dasatinib (Sprycel) in adult patients with newly diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
